29 Jul, 2005
Notice of Increase in Capital of Subsidiary
This is to notify that Takara Bio Inc. (president & CEO: Ikunoshin Kato, Ph.D.) increased the capital of a subsidiary which was set up in the U.S. to acquire Clontech operations (announced on July 1, 2005) at a board of directors meeting held on July 29, 2005.
- Content of the capital increase
To acquire Clontech operations (shares of Clontech Laboratories Inc. and assets related to such operations), we have decided to increase capital of
a subsidiary which we set up in the U.S.
- Outline of the subsidiary
| 1) | Trade name | Takara Bio USA Holdings Inc. |
| 2) | Location | Delaware, U.S.A. |
| 3) | Offices | Mountain View, California, USA
(c/o Clontech Laboratories Inc., 1290 Terra Bella Avenue, Mountain View, California 94043, USA) |
| 4) | Company representative | Ikunoshin Kato, Ph.D. |
| 5) | Established | July 25, 2005 |
| 6) | Date of capital increase | August 2005 (planned) |
| 7) | Capital after capital increasee | US$70,000 thousand (capital before capital increase: US$1) |
| 8) | Total No. of shares to be issued after capital increase | 100 shares (planned number after capital increase) |
| 9) | Shareholder | Takara Bio Inc. : 100% |
| 10) | Lines of business | Holding company (management of Clontech operations, etc.) |
| 11) | Year end | December |
- Future earnings forecast
As this subsidiary is a holding company to acquire Clontech operations, there will be a limited effect of establishment of this subsidiary on performance of the Company. In addition, once this subsidiary completes acquisition of Clontech operations, we will again make announcement.
About Takara Bio Inc.
Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin® reagent, which is a world-standard in gene therapy protocols. In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cell-based therapy, and agricultural biotechnology; and is committed preventing disease and improving the quality of life for all people through the use of biotechnology. Through strategic alliances with other industry leaders, the Company aims to extend its reach around the world. More information is available at http://www.takara-bio.com.
For more information:
Corporate Communications
Takara Bio Inc.
E-mail: bio-ir@takara-bio.co.jp
This article is translated from press release in Japanese for your convenience.
Forward-Looking Statements
Statements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors. Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, decline in selling power of the Company's existing and new products, disruptions to production, violations of our intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.
|
